Introduction
Despite a tough year in 2005 in terms of the regulatory environment and public opinion, with the withdrawal of Vioxx still at the forefront of peoples' minds, a number of leading pharmas continued to drive impressive growth. Biologicals continued to lead the market in terms of growth with Genentech's cancer focused portfolio driving the fastest growth in 2005 and forecast to do the same in 2006.

Scope
Examines the performance of the leading pharma companies in 2005 to reveal the winners and losers by sales growth and share price performance
Identifies the products driving market growth and considers the patent expiries that are expected to slow that growth over the coming year
Explores the key trends that will shape the pharmaceutical market in 2006 and beyond
Highlights
Genentech was the fastest growing of the top 50 pharma and biotech companies in 2005. The company has been one of the major success stories of the last few years, and backs up that reputation with an impressive 46.4% sales growth rate in 2005, building on sales of $3,749m in 2004. Datamonitor also forecasts it to have the fastest growth in 2006.

2005 was characterized by a lack of mega-mergers between the industry heavyweights, as the major players questioned the value of such huge-scale deals. Nevertheless, it has remained popular to make small, incremental acquisitions to acquire pipeline products or increase presence in specific therapeutic areas a trend expected to continue

While there were a number of new product launches in 2005, 2006 looks set to see the launch of products with greater potential. Sanofi-Aventis' Acomplia for the treatment of obesity and smoking cessation and Pfizer's inhalable insulin Exubera both have considerable sales potential

Reasons to Purchase
Benchmark the leading companies in terms of sales and share price performance in 2005
Uncover the products driving growth in the pharmaceutical industry as well as the key patent expiries likely to restrict it
Assess the key trends that will shape the future pharmaceutical market

Introduction
Despite a tough year in 2005 in terms of the regulatory environment and public opinion, with the withdrawal of Vioxx still at the forefront of peoples' minds, a number of leading pharmas continued to drive impressive growth. Biologicals continued to lead the market in terms of growth with Genentech's cancer focused portfolio driving the fastest growth in 2005 and forecast to do the same in 2006.

Scope
Examines the performance of the leading pharma companies in 2005 to reveal the winners and losers by sales growth and share price performance
Identifies the products driving market growth and considers the patent expiries that are expected to slow that growth over the coming year
Explores the key trends that will shape the pharmaceutical market in 2006 and beyond
Highlights
Genentech was the fastest growing of the top 50 pharma and biotech companies in 2005. The company has been one of the major success stories of the last few years, and backs up that reputation with an impressive 46.4% sales growth rate in 2005, building on sales of $3,749m in 2004. Datamonitor also forecasts it to have the fastest growth in 2006.

2005 was characterized by a lack of mega-mergers between the industry heavyweights, as the major players questioned the value of such huge-scale deals. Nevertheless, it has remained popular to make small, incremental acquisitions to acquire pipeline products or increase presence in specific therapeutic areas a trend expected to continue

While there were a number of new product launches in 2005, 2006 looks set to see the launch of products with greater potential. Sanofi-Aventis' Acomplia for the treatment of obesity and smoking cessation and Pfizer's inhalable insulin Exubera both have considerable sales potential

Reasons to Purchase
Benchmark the leading companies in terms of sales and share price performance in 2005
Uncover the products driving growth in the pharmaceutical industry as well as the key patent expiries likely to restrict it
Assess the key trends that will shape the future pharmaceutical market